Bing

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Trade-Ideas LLC identified NPS Pharmaceuticals ( NPSP) …
The Street · 9/2/2014
Healthcare stocks declined 0.5% on Wall Street on Monday. More broadly, the Dow Jones Industrial Average fell 1.8%, the Nasdaq was down 1.5% and the S&P 500 fell 1.8%. Some of the biggest gainers among healthcare stocks include …
Investor Place · 1/6/2015
The past year hasn't been the kindest to NPS Pharmaceuticals' (NASDAQ: NPSP.DL ) shareholders, with the stock vastly underperforming the broader market and its peers. Yet, take off your short-term blinders and examine NPS Pharmaceuticals' …
The Motley Fool · BySean Williams · 10/7/2014
More from Bing News
The stock has performed well over the last 12 months but has ... for its products to treat attention deficit hyperactivity disorder. The firm acquired NPS Pharmaceuticals earlier this year. Shire recently raised its full-year …
The Money Show · 8/25/2015
stock markets
NPS Pharmaceuticals, Inc. (NPSP) was a big mover last session, as its shares rose almost 14% on the day. This reverses the downtrend for the company since May 5, as the stock is now down nearly 4%. In the last 30 days, the company witnessed three …
Yahoo Finance · 5/12/2014
They are currently developing Natpara, a drug to be used to treat adult hypoparathyroidism, which affects 1% of the general population. NPSP data by YCharts The stock is down 6.36% YTD due to indecision regarding FDA approval of Natpara, though bullish ...
Seeking Alpha · 11/7/2014
NPS Pharmaceuticalsstock price jumped over 25% when the FDA released upbeat briefing materials on the company’s pipeline candidate Natpara ahead of the review by its Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC). The FDA …
ZACKS · 9/11/2014
following a rally in its stock. Shire PLC, Dublin-based specialty pharmaceutical company, is considered to be prime contestant in the process, given its expression of interest to takeover NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) in the past. Shire has ...
investcorrectly.com · 1/7/2015
The stock closed Friday at $33.28 a share. NPS Pharmaceuticals Inc. (NASDAQ: NPSP) CEO Francois Nader told Wall Street analysts to expect an FDA advisory panel to be held for its leading drug candidate Natpara before the Prescription Drug User …
24/7 Wall ST · 10/20/2014
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, today announced that NASDAQ has halted trading of the company's common stock.
Benzinga · ByEddie Staley · 9/12/2014